NCT03335774: A trial that was reported late by Nivagen Pharmaceuticals Inc.
This trial has reported, although it was 53 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03335774 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in the Treatment of Symptomatic Internal Hemorrhoids. |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 12, 2019 |
| Completion date | March 5, 2021 |
| Required reporting date | March 5, 2022, midnight |
| Actual reporting date | April 27, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 53 |